Cite
HARVARD Citation
Diab, A. et al. (n.d.). 368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors. Journal for immunotherapy of cancer. pp. A224-A225. [Online].